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In acute myeloid leukemia, there is growing evidence for splicing pat-tern deregulation, including differential expression of linear splice iso-forms of the commonly mutated gene nucleophosmin (NPM1). In this
study, we detect circular RNAs of NPM1 and quantify circRNA
hsa_circ_0075001 in a cohort of NPM1 wild-type and mutated acute
myeloid leukemia (n=46). Hsa_circ_0075001 expression correlates posi-
tively with total NPM1 expression, but is independent of the NPM1
mutational status. High versus low hsa_circ_0075001 expression defines
patient subgroups characterized by distinct gene expression patterns,
such as lower expression of components of the Toll-like receptor signal-
ing pathway in high hsa_circ_0075001 expression cases. Global evalua-
tion of circRNA expression in sorted healthy hematopoietic controls
(n=10) and acute myeloid leukemia (n=10) reveals circRNA transcripts
for 47.9% of all highly expressed genes. While circRNA expression cor-
relates globally with parental gene expression, we identify hematopoiet-
ic differentiation-associated as well as acute myeloid leukemia subgroup-
specific circRNA signatures.
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ABSTRACT
Introduction
Acute myeloid leukemia (AML) is the most common acute leukemia in adults
and despite recent progress in understanding leukemia biology, many patients
relapse and ultimately die of the disease.1 While AML is a genetically heteroge-
neous disease, it has become clear that not only changes at the genome level con-
tribute to AML pathogenesis. During the past few years, next-generation sequenc-
ing (NGS) has revealed an accumulation of mutations in genes regulating the splic-
ing process in approximately 10% of AML patients,2 and a large comprehensive
NGS study in AML determined AML patients with spliceosome mutations as a
clinically relevant distinct AML subgroup.3 This places a novel focus on alternative
and aberrant splicing events that seem to play a general role in AML, and an
improved understanding of these aberrations might harbor the potential for novel
treatment strategies.4
Aberrant splicing events might also impact the large subset of AML patients car-
rying a mutation in the nucleophosmin (NPM1) gene, which encodes a multifunction-
al chaperone protein involved in ribosomal biogenesis, apoptosis, and cell prolifer-
ation.5 In NPM1-mutated AML patients, an insertion into exon 12 of NPM1 leads
to an aberrant localization of the protein in the cytoplasm, which contributes to the
leukemogenic phenotype and is considered an AML-defining mutation.6,7
Moreover, there is evidence that both the impairment of NPM1 function due to
deletion or dislocation, and the enhancement of NPM1 function due to overexpres-
sion, can confer a tumorigenic effect.8,9 As NPM1 bears both proto-oncogene and
tumor-suppressor properties, its deregulation by means other than gene mutation
might also play a pathogenic role. 
Recently, it has been shown that, in AML, several alternatively spliced linear iso-
forms are produced from the NPM1 gene, of which a short R2 variant (NCBI
Reference Sequence: NM_001037738.2) was shown to be differentially expressed
S. Hirsch et al.
2040 haematologica | 2017; 102(12)
Figure 1. Characterization of circular NPM1 splice variants. (A) Predicted exon composition of linear and circular NPM1 splice variants, based on information pro-
vided in the AceView and circBase databases. Presence of reverse complementary sequences in the flanking introns of a particular circRNA was evaluated and is
indicated by red diamonds. (B) A PCR using divergent NPM1-specific primers was performed with cDNA of two AML cell lines and 1 healthy volunteer sample. 
(C) Sanger sequencing of a KASUMI-1 cell line PCR product and NCBI BLAST alignment confirmed the existence of a backsplice junction and non-canonical exon
order of a circular RNA-derived PCR product. (D) Detection of circNPM1 transcripts in leukemia cell lines (n=7) and healthy volunteers (HV, n=3) with backsplice-spe-
cific primers.  b-actin (ACTB) served as an internal control. IDs according to circBase and length of the expected amplicon are indicated. (E) Exon and intron compo-
sition of circNPM1 splice variants detected via Oxford Nanopore long-read sequencing of PCR products.
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in a large cohort of AML patients.10 Notably, there was
also an association between high NPM1 R2 expression
and better outcome in CN-AML patients, especially in
patients without concomitant FLT3-ITD mutation, there-
by providing further evidence that deregulated splicing
patterns might contribute to AML pathogenesis.
In addition to splicing events affecting protein coding
genes, recent transcriptome studies have revealed that
more than 60% of the human genome is transcribed and
reproducibly detected as RNA transcripts, while only 2%
of the genome codes for protein sequences.11 This implies
an important biological function and a need for more com-
prehensive analyses of the non-coding transcriptome. In
accordance with this, several studies have also pointed to
an important role for non-coding RNAs, such as
microRNAs (miRNA) and long non-coding RNAs
(lncRNA), in AML pathogenesis.12-14
Recently, a new class of non-coding RNAs termed circu-
lar RNAs (circRNAs) was discovered.15 CircRNAs are
abundant, highly conserved, and their expression is specif-
ically regulated, making them promising candidates for
biomarker research.15-17 CircRNAs are formed through a
ligation of the 5’ and the 3’ end of a transcript (so-called
backsplicing), which leads to a non-canonical order of
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Figure 2. Expression of circular NPM1 transcript hsa_circ_0075001 and impacts on gene expression in a cohort of 46 acute myeloid leukemia (AML) patients.
Expression of hsa_circ_0075001 and total NPM1 was measured in 46 AML patients by qPCR. All values are normalized to b-actin (ACTB) and are relative to the
respective mean expression. (A) Difference in hsa_circ_0075001 expression in AML patients allocated to the high (red) or low (blue) expression group (dichotomized
at the median; P<0.001, unpaired t-test). Black lines indicate the 25% percentiles. (B) Expression of hsa_circ_0075001 in relation to total NPM1 in the AML cohort.
(C) Principal component analysis of the distribution of global gene expression differences in AML patients allocated to the high (red) or low (blue) hsa_circ_0075001
expression group. (D) Key components of the Toll-like receptor (TLR) signaling pathway were down-regulated in patients with high hsa_circ_0075001 expression (red).
The heatmap illustrates gene expression of the top 20 genes of the TLR pathway with low expression colored purple and high expression colored yellow. Hierarchical
clustering of AML patients with high (red) or low (blue) hsa_circ_0075001 expression based on these genes. R: Pearson correlation coefficient; R²: coefficient of
determination. 
A B C
D
exons. Different mechanisms have been suggested for the
biogenesis of circRNAs, which are able to bring down-
stream donors into close proximity with upstream splice
acceptors, including binding sites for RNA-binding pro-
teins and reverse complementary sequences in flanking
introns.18,19 Given the general deregulation in splicing
mechanisms in AML, expression of circRNAs might also
be impaired in leukemia cells, and altered circRNAs could
contribute to leukemogenesis.20
In the current study, based on the relevance of NPM1 in
AML, we investigate the expression of circular NPM1
transcripts in both healthy hematopoietic and leukemic
cells. In addition to known NPM1 circRNAs (annotated in
the database circBase21), we provide evidence for novel
variants as well as NPM1 circRNAs differentially
expressed in AML, such as hsa_circ_0075001. Quantifying
the expression of hsa_circ_0075001 in a cohort of 46 AML
patients, we reveal NPM1 mutation-independent expres-
sion groups characterized by distinct gene expression pro-
files. This further suggests a potential functional relevance
of circular NPM1 transcripts and adds another level of
complexity to the multifaceted gene, NPM1. Via a more
comprehensive and unbiased RNA-Seq-based transcrip-
tome analysis, we gain additional insights into the circular
RNAome of the hematopoietic system, and determine
changes in the circRNA repertoire throughout myeloid
differentiation, as well as non-physiological patterns asso-
ciated with leukemic transformation.
Methods
Patient material and healthy controls
Acute myeloid leukemia patients were selected from a larger
cohort enrolled in the AMLSG_07-04 study (clinicaltrials.gov identi-
fier: 00151242). Informed patient consent was obtained for the
study and concomitant scientific investigations, and the research
was conducted after approval by the local ethical committee and
according to the principles of the Declaration of Helsinki.
Cytogenetically normal AML cases were selected for the quantifi-
cation of hsa_circ_0075001 (n=46) and for RNA-Seq (n=10). For
more detailed information please refer to the Online Supplementary
Methods and Online Supplementary Table S1.
Healthy control samples were collected from 6 individuals after
informed consent. For RNA-Seq, bone marrow samples of 3
healthy controls were FACS-sorted as previously described.22 
Oxford Nanopore sequencing
PCR products for Oxford Nanopore sequencing were generated
with outward facing, so-called divergent primers specific for
NPM1 (Online Supplementary Table S2), with product sizes ranging
from 150bp to 2500bp. 1 mg purified PCR product was subjected
to library preparation using the SQK-NSK007 Nanopore
Sequencing Kit (v.R9, Oxford Nanopore Technologies, Oxford,
UK), following the standard protocol for Amplicon sequencing for
the MinIONTM device. 135 ng of end-prepped DNA was subjected
to adapter ligation. Oxford Nanopore reads were aligned using
BWA-MEM23 and NCBI BLAST.24
Integration of gene expression data
The 46 AML patients were dichotomized based on the follow-
ing criteria: NPM1 mutational status [wild-type (wt) vs. mutated],
circNPM1 hsa_circ_0075001 expression (high vs. low, relative to
the median expression), or total NPM1 expression (high vs. low).
Principal component analysis (PCA) of microarray data was con-
ducted using the Partek® Genomics Suite® software (Partek, St.
Louis, MO, USA). One-way ANOVA was used to examine differ-
ences between the respective groups. Differentially expressed
genes were defined as log2FC>|0.6| and P<0.05 after controlling
the false discovery rate (FDR) using the Benjamini–Hochberg pro-
cedure. Pathway analysis was performed using the
iPathwayGuide web application (Advaita, Plymouth, MI, USA).
Statistical thresholds were set at P<0.05 and log2FC>|0.6|.
Microarray data are available at Gene Expression Omnibus (GEO;
accession number GSE104099).
RNA-Seq 
Libraries were prepared from 1 µg of input total RNA using the
TruSeq Stranded Total RNA Kit with Ribo-Zero
Human/Mouse/Rat (Illumina, San Diego, CA, USA) according to
the manufacturer’s instructions. The pooled RNA libraries were
sequenced on an Illumina HiSeq2000 with 100bp paired-end reads
and an average coverage of 62 (±24)x106 reads per sample. RNA-
Seq data were aligned and quantified using STAR.25 Reads derived
from circRNAs mapping to a backsplice junction were identified
using an in-house analysis pipeline detecting exons in a shuffled
order. A more detailed description of the pipeline is provided in
the Online Supplementary Methods. Circular reads were then nor-
malized and transformed to the logarithmic scale using DESeq226
and PCA was performed based on those 500 genes with the high-
est variance of circRNA expression across all samples. Genes dif-
ferentially expressing circRNAs were tested for log2FC>|0.6|, and
FDR<0.1 was set for correction of multiple comparisons. Gene set
enrichment analysis was performed using GSEA and the
Molecular Signatures Database (MsigDB).27 To calculate the per-
centage of genes which also produce circRNAs, the top 10,794
genes with a mean read count over 100 were considered as “highly
expressed” and the top 17,755 genes with a mean read count over
10 were considered “markedly expressed” (Online Supplementary
Figure S1).  Normalized RNA-Seq data are provided  in Online
Supplementary Tables S3 and S4.
Results
Circular NPM1 transcripts in leukemic and healthy
cells
Several linear and circular transcripts are known to be
transcribed from the NPM1 gene, but circRNA biogenesis
is only partly understood. An overview of variants as
annotated in the databases AceView28 for linear NPM1
transcripts and circBase21 for circRNAs is given in Figure
1A. Since reverse complementary intronic sequences, such
as inverted Alu repeats, are thought to be of importance
for the formation of the circle,16,29 we investigated the pres-
ence of such sequences in introns of the NPM1 gene
(ENSG00000181163) using NCBI BLAST.24 Moreover, we
assessed a possible correlation of the presence of reverse
complementary intronic sequences with exon combina-
tions that take part in backsplicing events. Out of 29
known NPM1 variants, we found reverse complementary
sequences in flanking introns of 13 (44.8%) annotated cir-
cular transcripts, possibly promoting their biogenesis
(Online Supplementary Table S5). However, we also found
inverse complementary sequences in introns that are not
known to take part in backsplicing events to form a
circRNA. Thus, reverse complementary intronic
sequences are not the only mechanism promoting
circRNA formation.
As a first experimental approach, we performed PCR
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with divergent primers in two NPM1 wt (NPM1wt)
leukemia cell lines, ME-1 and KASUMI-1, and one sample
derived from a healthy volunteer. Primers were designed
for exons of NPM1 which are located in the majority of
annotated circular NPM1 transcripts. This resulted in mul-
tiple PCR products of circular origin in all samples, reflect-
ing various circRNAs produced from the NPM1 gene
(Figure 1B). Validation by Sanger sequencing confirmed
the specificity for NPM1, the non-canonical exon order,
and the backsplice sequence of these circRNAs. A repre-
sentative example of a previously unknown circNPM1
variant detected in the KASUMI-1 cell line consists of
exons 8, 9, 11, and 12 with a backsplice junction located
between exons 12 and 8 of NPM1 (Figure 1C). 
Next, for the specific detection of individual circNPM1
transcripts, backsplice sequence-specific PCR primers
were designed, and the screening of cell lines was extend-
ed. In total, we analyzed six AML cell lines (including the
NPM1 mutant cell line OCI-AML3), one CML cell line in
terminal myeloid blast crisis, and 3 samples derived from
the peripheral blood mononuclear cell fraction of healthy
volunteers, and we were able to specifically amplify 15
circNPM1 variants. While some variants were uniformly
expressed among the control and leukemia samples,
including hsa_circ_0074997, _0075004, _0075005,
_0005341, _0075019 and _0075022, other variants showed
lower expression in healthy volunteers compared to
leukemia cell lines, such as hsa_circ_0074995, _0074998,
_0075001, _0075002 and _0075012 (Figure 1D). 
To gain insight into the internal structure of circRNAs,
we made use of the long-read Oxford Nanopore technol-
ogy to sequence circular-derived PCR products created
with NPM1-specific divergent primers. We detected
already annotated circNPM1 variants, including
hsa_circ_0074997, _0075000 and _0075004 (Figure 1E).
Moreover, we found novel variants that retained complete
introns, especially the complete intronic sequences
between exons 3 and 4 of NPM1, and between exons 5
and 6. Furthermore, parts of intron 1 were shown to take
part in backsplicing events, for example, with exon 6 and
parts of intron 2 (Figure 1E).
Hsa_circ_0075001 correlates with distinct gene
expression patterns
As circNPM1 75001 (circBase ID hsa_circ_0075001)
exhibited a highly differential expression pattern in the
AML cell lines, it was selected for quantitative screening in
a cohort of 46 AML patients in parallel to the expression
of total NPM1. No considerable difference could be
detected regarding the mean, median, and the range of
expression between NPM1wt (n=23) and NPM1 mutated
(NPM1mut, n=23) patients (Online Supplementary Figure
S2A and B). However, we observed high expression of
hsa_circ_0075001 in patients with no or minimal matura-
tion of the predominant blast population [subtypes M0 or
M1 according to the French-American-British (FAB) classi-
fication system] (Online Supplementary Figure S3).
Expression of hsa_circ_0075001 in patients with a more
mature blast population (M2, M4 and M5) was significant-
ly lower (median fold change=3; P<0.001, unpaired t-test). 
Across all AML samples, there was a 4-fold difference in
expression (P<0.0001, unpaired t-test) and patients were
allocated to a low and a high circNPM1 75001 expression
cohort based on the median (Figure 2A). Furthermore,
expression of hsa_circ_0075001 correlated strongly with
total NPM1 expression (Pearson correlation coefficient
R=0.72) (Figure 2B), raising the question of whether the
expression of circRNAs might generally be correlated with
that of the respective parental gene.
Gene expression profiling for the high versus low
hsa_circ_0075001 expression groups identified 2292 dif-
ferentially expressed (DE) genes between patients using
an FDR-corrected P<0.05 and a threshold for log2 fold
change (log2FC)>|0.6|. Unsupervised principal component
analysis (PCA) illustrates that the hsa_circ_0075001
expression status defined distinct subgroups of patients
(Figure 2C). One-way ANOVA confirmed significant dif-
ferences in gene expression between the high versus low
hsa_circ_0075001 expression groups, and a comparative
gene expression pathway analysis (statistical thresholds
for differential gene expression  set at P<0.05 and
log2FC>|0.6|) revealed significant differences in the expres-
sion of genes involved in the Toll-like receptor (TLR) sig-
naling pathway as an example. This pathway was signifi-
cantly down-regulated in patients with high
hsa_circ_0075001 expression compared to patients with
low hsa_circ_0075001 expression (FDR-corrected
P<0.0001) (Online Supplementary Table S6). A total of 94
genes were perturbed in this pathway, with the main dys-
regulated components of the pathway being several TLR
genes, such as TLR1, TRL4, TLR5, and TLR7/8, as well as
levels of co-receptors like CD14, and downstream adaptor
proteins like MYD88 (Figure 2D). Moreover, 185 differen-
tially expressed genes, whose expression was decreased in
patients with high hsa_circ_0075001 expression, are
known target genes of miR-181, such as Caspase recruit-
ment domain-containing protein 8 (CARD8), Caspase 1
(CASP1) Macrophage scavenger receptor 1 (MSR1) solute
carrier family 11 member 1 (SLC11A1), and TLR4. It is
known that miR-181 is commonly deregulated in cytoge-
netically normal AML.30
In contrast, a comparison of AML cases with high versus
low total NPM1 expression did not reveal an enrichment
of TLR signaling pathway genes among the top 40 path-
ways, but rather ribosomal protein genes being up-regu-
lated in patients with high total NPM1 expression (FDR-
corrected P<0.0001) (Online Supplementary Table S7).
Unbiased evaluation of the circular RNAome in AML
Given the differential expression of NPM1 circRNA in
AML, we aimed for a more global insight into circRNA
expression in hematopoietic cells. To this end, we per-
formed ribosomal RNA-depleted RNA-Seq of 10 AML
patients (n=5 NPM1mut and n=5 NPM1wt cases), and 10
FACS-sorted healthy control samples [n=4 immature
myeloid differentiation stages (myeloblasts and promye-
locytes), n=6 more mature myeloid differentiation stages
(metamyelocytes and neutrophils)]. Using an in-house
script for circRNA identification, in total, we detected
circRNAs for 31.7% (n=5635) out of 17,755 markedly
expressed genes (mean normalized read count >10 across
all 20 RNA-Seq samples) and for 47.9% (n=5173) out of
the 10,794 highly expressed genes (mean normalized read
count >100) (Online Supplementary Figure S1). While circu-
lar expression of many genes was comparable between
AML patients and healthy control samples (Pearson corre-
lation coefficient R=0.749) (Figure 3A), some genes partic-
ularly showed high circular expression in AML but not in
healthy samples, and vice versa.
In accordance with our previous finding for NPM1, we
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Figure 3. Circular RNAome in acute myeloid leukemia (AML) patients and healthy hematopoietic cells. Ribosomal RNA-depleted RNA-Seq of 5 NPM1mut, 5 NPM1wt
AML, and 10 healthy hematopoietic control samples. (A) Global circular gene expression in 10 AML patients compared to expression in 10 healthy controls. Circular-
derived reads were detected for 5694 genes. The x-value of each dot is the mean circular read count for the respective gene in 10 healthy samples; y-value repre-
sents the mean circular read count in 10 AML patient samples. y=x is plotted in gray. (B) Mean expression of circRNA transcripts relative to parental gene expression
of “markedly expressed” genes in 10 AML patients. The log2 of the mean normalized read counts across all 10 samples is shown. The linear regression function is
indicated. (C) Mean expression of circRNA transcripts relative to parental gene expression of “markedly expressed” genes in 10 healthy hematopoietic control sam-
ples. (D) CircRNA expression in AML patients compared to healthy control samples. Principal component analysis (PCA) of circRNA expression data of 5 NPM1mut
patients (red) and 5 NPM1wt patients (green), and 10 healthy control samples, of which 4 were derived from immature myeloid differentiation stages (blue:
myeloblasts and promyelocytes) and 6 from more mature myeloid differentiation stages (purple: metamyelocytes and neutrophils). PCA was performed based on the
500 genes with the highest variance across all samples. (E) Normalized circular read counts in 10 AML patients and 10 healthy control samples are shown for the
fms like tyrosine kinase 3 (FLT3) gene which is one of the genes differentially expressing circRNAs. (F) Correlation of circFLT3 expression with parental gene expres-
sion in 10 AML patients (red circles) and 10 healthy control samples (blue triangles). Values are shown as normalized read counts. R: Pearson correlation coefficient;
R²: coefficient of determination.
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again observed a tendency towards higher circRNA
expression in genes with higher parental gene expression
in both leukemia cells (Figure 3B) and healthy control cells
(Figure 3C). Nevertheless, there are genes that produce
only few or no circRNA transcripts despite high gene
expression levels, while others with lower parental gene
expression show comparatively high circRNA expression.
Furthermore, there was a slight, but distinct difference
between AML and healthy control cells with circRNAs for
46.7% of the highly expressed genes in AML and only
43.8% in normal cells (P=0.009, χ2 test).
AML patients and healthy controls differ in circRNA
signature
We performed PCA on the circular-derived RNA-Seq
data comparing AML with healthy control samples, and at
the same time contrasting NPM1mut and NPM1wt
patients and healthy myeloid cell samples of more mature
myeloblasts and promyelocytes, and more immature
metamyelocytes and neutrophils (Figure  3D). This analy-
sis showed that circRNA signatures are associated with
myeloid differentiation and are distinct in leukemic cells,
which is reflected in the fact that AML samples do not
merely resemble immature myeloid cells. Although there
was no difference in circNPM1 expression, NPM1mut
patients could be distinguished from NPM1wt patients
based on their global circRNA expression. 
In total, differentially expressed circRNAs from 27 genes
were found comparing AML to healthy control samples
(P<0.05) (Online Supplementary Table S8). Notably, these
genes were significantly enriched for the 
RADMACHER_AML_PROGNOSIS gene set 
(FDR-corrected P<0.05, GSEA) based on the differential
expression of angiopoietin 1 (ANGPT1; log2FC=3.3), 
UDP-glucose ceramide glucosyltransferase 
(UGCG; log2FC=-3.5), and fms related tyrosine kinase 3
(FLT3; log2FC=3.4) circRNAs. Among 14 genes with high-
er circRNA expression in AML  (log2FC range 2.1-4.7), the
most significantly deregulated circRNAs were produced
from genetic suppressor element 1 (GSE1; log2FC=4.3) and
FLT3 (see above). Circular-derived FLT3 reads mainly
mapped to three different variants: two already annotated
variants (hsa_circ_0100163, hsa_circ_0100164) and one
novel variant with a backsplice sequence between exons
19 and 16 of FLT3. Since FLT3 is often mutated and con-
stitutively activated in AML,3 we were particularly inter-
ested in circFLT3 expression in AML patients compared to
healthy cells (Figure 3E). The correlation of total circFLT3
expression with parental gene expression was high in
healthy samples (Pearson correlation coefficient R=0.98),
whereas this was not observed in AML samples (Pearson
correlation coefficient R=0.21) (Figure 3F). 
Discussion
Here, we investigated circRNA expression of one of the
most frequently mutated genes in AML. In agreement
with others who detected alternative splicing events in
circRNAs,31 we found that there are many different
circRNA variants for NPM1 that comprise non-canonical
exon and intron sequences. Previously, circRNAs were
predicted based on non-canonical exon-exon junctions
found by RNA-Seq.15,17 Using a new technology for long-
read sequencing, Oxford Nanopore, we elucidated the
internal structure of several circNPM1 variants for the first
time in AML and demonstrated the power of this novel
approach. We could show that, in addition to canonical
exons, some variants retained full introns. Moreover, we
found parts of intronic sequences taking part in backsplic-
ing events. Since these sequences have not been taken into
account in many circRNA studies so far, backsplice events
between canonical exons and intronic sequences have
probably been under-estimated. 
Besides intronic sequences, we also detected truncated
alternative exons of NPM1, which participated in forming
the fusion site (truncated versions of exons 2, 5, 7, 8 and
12). In this context, it would be of interest to study the
possible effects of splicing mutations in AML on the for-
mation and the internal structure of circRNAs. Moreover,
future elucidation of circRNA function will help to under-
stand the potential necessity of the large circRNA variety
and their role in AML.
Quantification of the circNPM1 variant
hsa_circ_0075001 and integration of global gene expres-
sion data revealed a distinct hsa_circ_0075001-associated
gene expression signature, pointing to a biological rele-
vance of this circRNA. High hsa_circ_0075001 expression
was highly associated with a significantly lower expres-
sion of genes involved in the TLR signaling pathway.
While TLRs form a critical part of the innate immune
response, they have recently been implicated in the differ-
entiation of normal hematopoietic cells. Furthermore,
TLR1 expression has been linked to leukemic stem cell sur-
vival in AML, as well as enhanced TLR1/TLR2 activation
in leukemic stem cell differentiation.32-34 This is in line with
our observation that high hsa_circ_0075001 expression is
associated with low TLR gene expression and a more
immature phenotype of the AML blasts. Future functional
experiments will be needed to show whether in AML, the
TLR pathway deregulation is in part caused by aberrant
expression of circRNAs, such as hsa_circ_0075001, or
whether the respective circRNA expression changes are in
turn secondary to TLR-deregulation, for example, as a
marker for differentiation.
Interestingly, Marcucci et al. have shown that the
expression of TLR signaling pathway genes is associated
with prognostically relevant microRNA signatures in
AML.35 In particular, the expression levels of miRNA-181
family members were inversely correlated with the
expression levels of the TLR signaling pathway genes. In
our study, we found that the expression of various known
miR-181 target genes was significantly decreased in
patients with high hsa_circ_0075001 expression. Since the
NPM1 gene contains binding sites for miR-181,36 it would
be of great interest to investigate whether circular NPM1
transcripts interact with members of the miR-181 family
and thereby influence the expression of genes involved in
the TLR signaling pathway. 
In contrast, the TLR signaling pathway was not among
the top 40 pathways associated with total NPM1 expres-
sion, although its deregulation could be detected at a
weaker level considering the positive correlation of total
NPM1 and hsa_circ_75001 expression. However, the fact
that the signature is more pronounced in patients with
high hsa_circ_75001 expression supports the view that
circRNA expression is the decisive factor correlating with
TLR pathway deregulation. 
Among the linear-driven NPM1 pathways, we found
that ribosomal protein genes were strongly up-regulated
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in patients with high total NPM1 expression. Since NPM1
is closely involved in the biogenesis of ribosomes, this
finding supports the accuracy and fidelity of our pathway
analysis. Moreover, these findings underline the conceiv-
ably different functions and impacts of circular and linear
NPM1 transcripts. While we could show correlation of
circNPM1 variant expression and distinct gene expression
patterns, the significance of the respective NPM1 variants
is still unknown, and further studies are warranted to
study the impact of circular NPM1 RNAs on regulation of
gene expression.
With regard to circRNA biogenesis, complementary
intronic sequences are most likely not the only key mech-
anism. This is consistent with findings of such sequences
in only around half of the circNPM1 variants. Whether
circRNA expression is directly linked to the transcription
of the linear isoforms of a gene is still an issue of current
research and might not be consistent for all genes. The
much longer half life of circular transcripts compared to
their linear counterparts, as well as impairment of the
splicing machinery, might also impact findings. In our
study, a positive correlation was found for
hsa_circ_0075001 and total NPM1 expression. In line with
this, RNA-Seq data revealed a general correlation of
circRNA and parental gene expression. However, we also
found many exceptions. Not all highly expressed genes
produce circRNAs, and those circRNAs with the highest
expression level are generally not derived from genes with
highest mRNA expression. Moreover, circFLT3 expression
did correlate with parental gene expression only in
healthy samples, but not in AML cells, thereby further
pointing towards a non-random deregulation of circRNAs
in AML, independent of mRNA expression.
Circular RNAs have been shown to be tightly regulated
in the course of differentiation. Hundreds of circRNAs are,
for example, differentially expressed during epithelial-mes-
enchymal transition,37 and circRNAs are globally up-regu-
lated during neuronal differentiation.38 For the first time, we
have shown that the expression of circRNAs, in line with
mRNA, miRNA and lncRNA expression, is deregulated in
AML, a disease characterized by inadequate differentiation
of hematopoietic progenitor cells. We detected AML-asso-
ciated and differentiation-independent differences between
healthy hematopoietic cells and AML cells, and could also
distinguish different AML subgroups based on their
circRNA expression profile. These differences might in part
be explained by the different degree of differentiation of the
leukemia-initiating cells, but also by the genomic alter-
ations influencing splicing factors and epigenetic modula-
tors. As a consequence, the determination of the circular
RNAome provides additional valuable insights into the
biology of a leukemic cell. Furthermore, circRNAs are more
stable than their linear mRNA counterparts,39,40 and thus
could serve as potential biomarkers for classification and
risk stratification in AML. In the future, additional studies
will  be  required: i) to further determine the biological func-
tion of circRNA candidates in both healthy and malignant
tissue; and ii) to define the prognostic and predictive impact
of circRNA signatures in AML. 
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